

LRRC62 Polyclonal Antibody

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP58760

Product Information

Application WB, IHC-P, IHC-F, IF, ICC, E

Primary Accession Q5R3F8

Reactivity Rat, Pig, Dog, Bovine

Host Rabbit
Clonality Polyclonal
Calculated MW 89687
Physical State Liquid

Immunogen KLH conjugated synthetic peptide derived from human LRRC62

Epitope Specificity 301-400/820

Isotype IgG

Purity affinity purified by Protein A

Buffer 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

SUBCELLULAR LOCATION Membrane; Single-pass membrane protein(Potential).

SIMILARITY Contains 1 fibronectin type-III domain.Contains 5 LRR (leucine-rich)

repeats. Contains 1 LRRCT domain.

SUBUNIT Interacts with PPP1CA.

Important Note This product as supplied is intended for research use only, not for use in

human, therapeutic or diagnostic applications.

Background Descriptions LRRC62 contains 1 fibronectin type III domain and 5 LRR (leucine rich)

repeats. The exact function of LRRC62 remains unknown.

Additional Information

Gene ID 114794

Other Names Protein phosphatase 1 regulatory subunit 29, Extracellular leucine-rich repeat

and fibronectin type III domain-containing protein 2, Leucine-rich repeat and

fibronectin type-III domain-containing protein 6, Leucine-rich repeat-containing protein 62, ELFN2, KIAA1904, LRRC62, PPP1R29

Dilution WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,ICC=1:100-500,IF=1:100-50

0,ELISA=1:5000-10000

Format 0.01M TBS(pH7.4) with 1% BSA, 0.09% (W/V) sodium azide and 50% Glyce

Storage Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When

reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody

is stable for at least two weeks at 2-4 °C.

Protein Information

Name ELFN2

Synonyms KIAA1904, LRRC62, PPP1R29

Function Inhibits phosphatase activity of protein phosphatase 1 (PP1) complexes.

Cellular Location Membrane; Single-pass membrane protein

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.